GO:0060546 negative regulation of necroptotic process: Cell Death Checkpoint, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060546 describes any process that decreases the rate, frequency or extent of necroptosis, a programmed necrotic cell death triggered by death domain receptors or Toll-like receptors.
• The core necroptotic machinery is the RIPK1/RIPK3/MLKL axis; negative regulation often targets RIPK1 kinase activity, RIPK3 stability, or MLKL phosphorylation.
• Multiple checkpoints suppress necroptosis, including A20-mediated restriction of PANoptosis, RUBCNL/PACER repression of RIPK1-dependent death, and CHMP4C inhibition of the RIPK1/RIPK3/MLKL pathway.
• Dysregulated negative regulation of necroptosis contributes to atherosclerosis, diabetic heart injury, preeclampsia, pancreatic cancer progression, and inflammatory cell death syndromes.
• Key experimental models include RIPK1/RIPK3/MLKL knockout and point-mutant cells, tagged knock-ins for ubiquitination studies, and overexpression of negative regulators such as A20 or CHMP4C.
• CRISPR screening and bioinformatics can identify novel suppressors of necroptosis and map their epistatic relationships within PANoptosis and inflammatory death networks.
Description
Necroptosis is a regulated form of necrotic cell death that depends on the activation of endogenous signaling pathways downstream of death domain receptors or Toll-like receptors. Because unrestrained necroptosis releases damage-associated molecular patterns and drives inflammation, cells deploy multiple braking systems to keep this pathway in check. The Gene Ontology term GO:0060546, negative regulation of necroptotic process, captures all molecular events that decrease the rate, frequency or extent of necroptosis. Understanding this term is essential for researchers studying inflammatory diseases, cancer, and tissue injury, where tipping the balance toward or away from necroptosis can determine cell fate and disease outcome.
negative regulation of necroptotic process At A Glance
| GO ID | GO:0060546 |
|---|---|
| GO term | negative regulation of necroptotic process |
| Ontology | biological_process |
| Synonym | negative regulation of necroptosis |
| Major function | Suppression of RIPK1/RIPK3/MLKL-dependent necroptotic cell death |
| Key regulators | A20, RUBCNL/PACER, CHMP4C, TAK1, NEDD4, CNP, CB2 receptor |
| Associated diseases | Atherosclerosis, diabetic heart injury, preeclampsia, pancreatic cancer, inflammatory PANoptosis |
| Research methods | CRISPR KO/point mutation/knock-in, overexpression, CRISPR library screening, bioinformatics |
What Is GO:0060546?
GO:0060546 (negative regulation of necroptotic process) is a biological process term defined as any process that decreases the rate, frequency or extent of a necroptotic process, a necrotic cell death process that results from the activation of endogenous cellular processes, such as signaling involving death domain receptors or Toll-like receptors. In practice, this includes protein-protein interactions, post-translational modifications, and transcriptional programs that inhibit RIPK1 kinase activity, destabilize RIPK3, prevent MLKL activation, or block downstream membrane permeabilization.
Why Is negative regulation of necroptotic process Important in Cell Biology?
Negative regulation of necroptosis is a critical cell death checkpoint because excessive or misplaced necroptosis drives inflammatory tissue damage, while insufficient suppression can promote tumor progression and immune evasion. The pathway intersects with apoptosis, pyroptosis, and PANoptosis, making it a central node in inflammatory cell death networks. Therapeutic strategies that enhance or restore negative regulation may protect against atherosclerosis, diabetic cardiomyopathy, and preeclampsia, whereas inhibiting these brakes could sensitize cancers to necroptosis-inducing therapies.
• Prevents uncontrolled inflammation by limiting RIPK1/RIPK3/MLKL signaling.
• Protects against atherosclerosis by dampening macrophage inflammatory responses.
• Limits diabetic heart injury by suppressing necroptosis in cardiomyocytes.
• Regulates trophoblast survival in preeclampsia via TAK1 ubiquitination.
• Restrains pancreatic cancer progression by inhibiting necroptosis.
• Controls PANoptosis and pathogen release in infectious disease models.
• Provides therapeutic targets for inflammatory and cardiovascular diseases.
• Offers biomarkers for cancer prognosis and treatment response.
• Enables CRISPR screening to discover novel necroptosis suppressors.
• Links cell death regulation to autophagy and DNA damage responses.
What Happens During negative regulation of necroptotic process?
Inhibition of RIPK1 kinase activity
In simple terms: The first brake stops RIPK1 from becoming an active kinase.
Negative regulation of necroptosis frequently begins with suppression of RIPK1 kinase activity. RUBCNL/PACER represses RIPK1 kinase-dependent apoptosis and necroptosis, acting as an autophagy protein that restrains death receptor signaling. A20 restricts PANoptosis through negative regulation of the necroptotic arm, limiting RIPK1-dependent cell death. These checkpoints prevent RIPK1 from phosphorylating downstream substrates and assembling the necrosome.
Destabilization of RIPK3 and the necrosome
In simple terms: The second brake removes or destabilizes RIPK3 so the death complex cannot form.
Once RIPK1 is active, it can interact with RIPK3 to form the necrosome. Negative regulators target RIPK3 stability and complex assembly. CHMP4C promotes pancreatic cancer progression by inhibiting necroptosis via the RIPK1/RIPK3/MLKL pathway, effectively blocking necrosome function. Thrombospondin-1 regulates trophoblast necroptosis through NEDD4-mediated ubiquitination of TAK1, which indirectly controls RIPK3 activation. These mechanisms ensure that even if RIPK1 escapes the first checkpoint, the necrosome cannot propagate death signals.
Prevention of MLKL activation and membrane permeabilization
In simple terms: The third brake stops MLKL from punching holes in the cell membrane.
MLKL is the executioner of necroptosis; its phosphorylation and oligomerization lead to membrane rupture. Negative regulation of necroptotic process includes mechanisms that prevent MLKL activation. CHMP4C inhibits the RIPK1/RIPK3/MLKL pathway, thereby blocking MLKL-mediated membrane permeabilization. Similarly, A20-mediated restriction of PANoptosis prevents downstream MLKL activation. These checkpoints are essential to avoid accidental cell lysis and inflammation.
Cross-talk with autophagy and DNA damage responses
In simple terms: Other cellular stress pathways can reinforce the brakes on necroptosis.
Negative regulation of necroptosis is integrated with autophagy and DNA damage responses. RUBCNL/PACER, an autophagy protein, represses RIPK1 kinase-dependent apoptosis and necroptosis, linking autophagic machinery to necroptosis suppression. MRE11 liberates cGAS from nucleosome sequestration during tumorigenesis, connecting DNA damage sensing to innate immune and cell death pathways that can influence necroptosis. These interactions show that negative regulation is not a single switch but a network of stress-responsive checkpoints.
Metabolic and receptor-mediated control
In simple terms: Metabolic signals and surface receptors can also apply the brakes.
Metabolic and receptor signals modulate negative regulation of necroptosis. CNP ameliorates macrophage inflammatory response and atherosclerosis, indirectly limiting necroptotic death in plaques. Cannabinoid receptor 2 (CB2) drives a molecular feedback loop that controls necroptosis in diabetic heart injuries, where receptor signaling influences the balance of death and survival. These examples highlight that negative regulation can be triggered by extracellular cues and metabolic state.
Key Genes Involved in GO:0060546 negative regulation of necroptotic process
The following genes and proteins are experimentally implicated in negative regulation of necroptotic process, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RIPK1 | Core necroptosis kinase; its activity is suppressed by negative regulators | Target for KO and point-mutation studies of necroptosis checkpoints |
| RIPK3 | Necrosome component; destabilized by negative regulators | Knockout and tagged knock-in models for ubiquitination studies |
| MLKL | Executioner of necroptosis; inhibited by negative regulators | Point-mutation and knock-in models for phosphorylation studies |
| A20 (TNFAIP3) | Restricts PANoptosis and negative regulation of necroptosis | Overexpression and KO models in inflammatory disease |
| RUBCNL/PACER | Autophagy protein repressing RIPK1-dependent apoptosis and necroptosis | KO and overexpression models in autophagy-necroptosis cross-talk |
| CHMP4C | Inhibits necroptosis via RIPK1/RIPK3/MLKL pathway | KO and overexpression in pancreatic cancer models |
| TAK1 (MAP3K7) | Regulated by NEDD4-mediated ubiquitination in trophoblast necroptosis | Knock-in and point-mutation models for ubiquitination sites |
| NEDD4 | E3 ubiquitin ligase targeting TAK1 in preeclampsia | KO and overexpression models for ubiquitination studies |
| CNP | Ameliorates macrophage inflammatory response and atherosclerosis | KO and overexpression in atherosclerosis models |
| CB2 receptor (CNR2) | Drives feedback loop controlling necroptosis in diabetic heart | KO and knock-in models for receptor signaling |
| MRE11 | Liberates cGAS from nucleosome sequestration during tumorigenesis | KO and point-mutation models for DNA damage responses |
| cGAS (CGAS) | Innate immune sensor linked to MRE11 and cell death | Knock-in and reporter models for innate immune signaling |
| Thrombospondin-1 (THBS1) | Regulates trophoblast necroptosis via TAK1 ubiquitination | KO and overexpression in preeclampsia models |
| PANoptosis regulators | Integrated cell death network including necroptosis | CRISPR library screening for novel suppressors |
| Small-molecule targets | Compounds modulating PANoptosis and necroptosis | Drug screening and target validation |
| Inflammatory cytokines | Downstream of necroptosis; modulated by negative regulators | Reporter assays and cytokine profiling |
| Autophagy machinery | Cross-talk with necroptosis suppression | KO and overexpression models for autophagy genes |
| Ubiquitin-proteasome components | Mediate degradation of necroptosis effectors | Knock-in and point-mutation models for ubiquitination |
How Is negative regulation of necroptotic process Regulated?
Negative regulation of necroptotic process is controlled at multiple levels. Post-translational modifications, especially ubiquitination, play a central role: NEDD4-mediated ubiquitination of TAK1 regulates trophoblast necroptosis, and A20 restricts PANoptosis through negative regulation of the necroptotic arm. Autophagy proteins such as RUBCNL/PACER repress RIPK1 kinase-dependent apoptosis and necroptosis, linking autophagic flux to necroptosis suppression. Receptor signaling, including cannabinoid receptor 2, drives a molecular feedback loop that controls necroptosis in diabetic heart injuries. Metabolic and inflammatory cues, such as CNP in macrophages, further modulate the threshold for necroptotic death. Together, these layers ensure that necroptosis is activated only when appropriate and is rapidly shut down to prevent inflammatory damage.
negative regulation of necroptotic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CNP | Atherosclerosis | ApoE-/- or LDLR-/- mouse models with CNP KO/overexpression |
| CB2 receptor (CNR2) | Diabetic heart injury | Streptozotocin-induced diabetic mice with CB2 KO/knock-in |
| THBS1/NEDD4/TAK1 | Preeclampsia | Trophoblast cell lines and placental explants with KO/point mutations |
| CHMP4C | Pancreatic cancer | Patient-derived xenografts and pancreatic cancer cell lines with CHMP4C KO/overexpression |
| A20 (TNFAIP3) | PANoptosis and infectious disease | Macrophage and epithelial cell models with A20 KO/overexpression |
Atherosclerosis and cardiovascular disease
Negative regulation of necroptosis protects against atherosclerosis by limiting macrophage inflammatory responses. CNP ameliorates macrophage inflammatory response and atherosclerosis, indicating that enhancing this brake could reduce plaque inflammation. In diabetic heart injuries, cannabinoid receptor 2-centric molecular feedback loops drive necroptosis, and disrupting this regulation exacerbates cardiac damage. These findings suggest that therapies boosting negative regulation of necroptosis may have cardiovascular benefits.
Preeclampsia and placental disorders
In preeclampsia, thrombospondin-1 regulates trophoblast necroptosis via NEDD4-mediated ubiquitination of TAK1. Dysregulated negative regulation of necroptosis in trophoblasts contributes to placental dysfunction and disease pathogenesis. Targeting this pathway may offer new strategies for preeclampsia treatment.
Cancer progression and therapy resistance
CHMP4C promotes pancreatic cancer progression by inhibiting necroptosis via the RIPK1/RIPK3/MLKL pathway, demonstrating that cancer cells can hijack negative regulation to evade cell death. MRE11 liberates cGAS from nucleosome sequestration during tumorigenesis, linking DNA damage responses to innate immune and cell death regulation. Understanding these mechanisms could inform therapies that disable necroptosis brakes in tumors.
Inflammatory cell death and PANoptosis
A20 restricts PDCoV release through negative regulation of PANoptosis, a cell death network that includes necroptosis. PANoptosis mechanisms and small-molecule compounds that modulate them are active areas of drug discovery. Negative regulation of necroptosis is therefore a key component of broader inflammatory cell death control.
From negative regulation of necroptotic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene enhance necroptosis? | CRISPR knockout in RIPK1/RIPK3/MLKL-competent cells |
| Does a specific phosphorylation site regulate negative regulation? | CRISPR point mutation (e.g., kinase-dead or phospho-dead) |
| Does ubiquitination of TAK1 control necroptosis? | Knock-in of ubiquitin-deficient TAK1 mutants |
| Where does a negative regulator localize during necroptosis? | Tagged knock-in (e.g., GFP or HA) for imaging |
| Can overexpression of a suppressor protect against necroptosis? | Doxycycline-inducible overexpression in disease-relevant cells |
| Which novel genes suppress necroptosis? | Genome-wide CRISPR library screening with necroptosis inducers |
How to Study the negative regulation of necroptotic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on necroptosis | Validate candidate negative regulators |
| CRISPR point mutation | Specific residue or domain requirements | Dissect kinase or ubiquitination sites |
| Knock-in (tagged) | Protein localization and interactions | Imaging and proximity labeling |
| Overexpression | Gain-of-function protection | Test therapeutic potential |
| CRISPR library screening | Genome-wide suppressor discovery | Identify novel necroptosis brakes |
| Bioinformatics | Pathway and network analysis | Integrate screening and omics data |
| Immunoblotting | RIPK1/RIPK3/MLKL phosphorylation | Monitor necroptosis activation |
| Cell viability assays | Necroptosis extent | Quantify negative regulation |
CRISPR knockout and point-mutation studies
CRISPR knockout of candidate negative regulators such as A20, RUBCNL/PACER, or CHMP4C can reveal whether they are required to suppress necroptosis. Point mutations in RIPK1, RIPK3, or MLKL can dissect which domains or phosphorylation sites are targeted by these regulators. These approaches provide causal evidence linking specific genes to GO:0060546.
Knock-in and tagged knock-in models
Knock-in of ubiquitin-deficient TAK1 mutants or tagged versions of negative regulators allows precise tracking of post-translational modifications and localization during necroptosis. Tagged knock-ins (e.g., GFP, HA, or BirA) enable imaging and proximity labeling to identify interacting partners. These models are essential for mechanistic studies of negative regulation.
Overexpression and rescue experiments
Overexpression of negative regulators such as CNP, CB2 receptor, or CHMP4C can test whether increasing their levels protects against necroptosis in disease models. Rescue experiments in knockout backgrounds can confirm specificity. These studies help validate therapeutic strategies that boost negative regulation.
CRISPR library screening and bioinformatics
Genome-wide CRISPR library screening with necroptosis inducers can identify novel suppressors and map genetic interactions. Bioinformatics analysis of screening data, combined with pathway enrichment, can reveal networks connecting necroptosis to PANoptosis and autophagy. These unbiased approaches accelerate discovery of new components of GO:0060546.
How CRISPR Can Be Used to Study GO:0060546 negative regulation of necroptotic process
Knockout
CRISPR knockout of genes such as A20, RUBCNL/PACER, or CHMP4C can test whether they are required for negative regulation of necroptosis. Loss of these genes typically sensitizes cells to necroptosis inducers, confirming their suppressive role. Knockout models are also used to validate screening hits.
Point Mutation
Point mutations in RIPK1, RIPK3, MLKL, or TAK1 can define the exact residues targeted by negative regulators. For example, phospho-dead or ubiquitin-deficient mutants can reveal whether specific modifications are required for suppression. These models provide mechanistic insight into GO:0060546.
Knock-in
Knock-in of tagged or mutant alleles allows precise tracking of negative regulators in their endogenous context. Tagged knock-ins enable imaging and interactome studies, while mutant knock-ins test the function of specific domains. These models are invaluable for studying dynamic regulation of necroptosis.
Overexpression
Overexpression of negative regulators such as CNP, CB2 receptor, or CHMP4C can protect cells from necroptosis and reduce disease severity in models. Inducible overexpression systems allow temporal control of suppression. These experiments support therapeutic strategies that enhance negative regulation.
How EDITGENE Supports negative regulation of necroptotic process Research
Researchers studying negative regulation of necroptotic process-related genes often need to determine whether a candidate gene is causally involved in suppressing necroptosis or is merely a bystander. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of necroptotic process research.
Frequently Asked Questions About negative regulation of necroptotic process
What is negative regulation of necroptotic process?
It is the biological process that decreases the rate, frequency or extent of necroptosis, a programmed necrotic cell death triggered by death domain receptors or Toll-like receptors.
What is the GO ID for negative regulation of necroptotic process?
The GO ID is GO:0060546.
What genes are involved in negative regulation of necroptotic process?
Key genes include A20, RUBCNL/PACER, CHMP4C, TAK1, NEDD4, CNP, and CB2 receptor, among others.
How does RIPK1/RIPK3/MLKL signaling relate to negative regulation of necroptosis?
Negative regulators often inhibit RIPK1 kinase activity, destabilize RIPK3, or prevent MLKL activation to block necroptosis.
What diseases are linked to defective negative regulation of necroptosis?
Atherosclerosis, diabetic heart injury, preeclampsia, pancreatic cancer, and inflammatory PANoptosis have been linked to dysregulated necroptosis suppression.
How can CRISPR be used to study negative regulation of necroptotic process?
CRISPR knockout, point mutation, knock-in, and overexpression models can test whether specific genes suppress necroptosis in disease-relevant cells.
What is the role of A20 in negative regulation of necroptosis?
A20 restricts PANoptosis through negative regulation of the necroptotic arm, limiting inflammatory cell death.
How does RUBCNL/PACER affect necroptosis?
RUBCNL/PACER represses RIPK1 kinase-dependent apoptosis and necroptosis, linking autophagy to necroptosis suppression.
What experimental models are used to study negative regulation of necroptosis?
Common models include CRISPR knockout and point-mutant cell lines, tagged knock-ins, overexpression systems, and CRISPR library screens.
Why is negative regulation of necroptosis important for cancer therapy?
Cancer cells can hijack negative regulators such as CHMP4C to evade necroptosis; targeting these brakes may sensitize tumors to cell death.
Conclusion
GO:0060546 negative regulation of necroptotic process is a central checkpoint that prevents excessive inflammatory cell death while also being exploited by cancer cells to survive. The RIPK1/RIPK3/MLKL axis is controlled by multiple negative regulators, including A20, RUBCNL/PACER, CHMP4C, and TAK1-ubiquitination pathways, with broad implications for cardiovascular disease, preeclampsia, cancer, and infection. CRISPR-based models and library screening are powerful tools to dissect these mechanisms and identify new therapeutic targets.
References
- 1. Bao Q et al.. 2024. CNP Ameliorates Macrophage Inflammatory Response and Atherosclerosis.. Circ Res 134(8):e72-e91 PMID: 38456298
- 2. Wang L et al.. 2023. Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases.. Cell Death Dis 14(12):851 PMID: 38129399
- 3. Rojas-Rivera D et al.. 2024. The autophagy protein RUBCNL/PACER represses RIPK1 kinase-dependent apoptosis and necroptosis.. Autophagy 20(11):2444-2459 PMID: 38873940
- 4. Gao P et al.. 2023. Cannabinoid Receptor 2-Centric Molecular Feedback Loop Drives Necroptosis in Diabetic Heart Injuries.. Circulation 147(2):158-174 PMID: 36448459
- 5. Cho MG et al.. 2024. MRE11 liberates cGAS from nucleosome sequestration during tumorigenesis.. Nature 625(7995):585-592 PMID: 38200309
- 6. Hu H et al.. 2024. Thrombospondin-1 Regulates Trophoblast Necroptosis via NEDD4-Mediated Ubiquitination of TAK1 in Preeclampsia.. Adv Sci (Weinh) 11(21):e2309002 PMID: 38569496
- 7. Yu L et al.. 2025. CHMP4C promotes pancreatic cancer progression by inhibiting necroptosis via the RIPK1/RIPK3/MLKL pathway.. J Adv Res 77:653-668 PMID: 39870301
- 8. Lu C et al.. 2026. A20 restricted PDCoV release through negative regulation of PANoptosis.. mBio 17(4):e0008126 PMID: 41773863
